COGENTIN INJECTION Rx
Generic Name and Formulations:
Benztropine mesylate 1mg/mL; soln for IM or IV inj.
Indications for COGENTIN INJECTION:
Adjunct in Parkinsonism, drug-induced extrapyramidal disorders.
Parkinsonism: initially 0.5–1mg at bedtime. May increase by 0.5mg at 5–6 day intervals; max 6mg daily. Extrapyramidal disorders: 1–4mg 1–2 times daily. Acute dystonic reactions: 1–2mg IM or IV.
See Contraindications. Use cautiously in older children.
Children <3yrs old.
Tardive dyskinesia: not recommended. Narrow-angle glaucoma. Tachycardia. Psychosis. Prostatic hypertrophy. GI or GU obstruction. Chronically ill. Alcoholics. CNS disease. Exposure to extreme heat. Elderly. Pregnancy.
Paralytic ileus, hyperthermia, heat stroke with phenothiazines, tricyclic antidepressants. Antagonizes psychotropics.
Anticholinergic and antihistaminic effects, weakness, confusion, anhidrosis, excitement, GI upset, depression, lethargy, heat stroke, dysuria, toxic psychosis, rash.
Tabs formerly known under the brand name Cogentin.
Tabs—contact supplier; Amps—(5 x 2mL)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy